venBio Partners LLC Trims Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

venBio Partners LLC reduced its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 539,194 shares of the company's stock after selling 75,400 shares during the quarter. Harmony Biosciences makes up 10.9% of venBio Partners LLC's portfolio, making the stock its 3rd biggest position. venBio Partners LLC owned approximately 0.95% of Harmony Biosciences worth $18,554,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HRMY. FMR LLC increased its holdings in shares of Harmony Biosciences by 1.9% in the 4th quarter. FMR LLC now owns 5,329,902 shares of the company's stock worth $183,402,000 after acquiring an additional 101,182 shares during the period. Vanguard Group Inc. increased its holdings in shares of Harmony Biosciences by 36.4% in the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after acquiring an additional 1,262,362 shares during the period. Pacer Advisors Inc. increased its holdings in shares of Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. Deep Track Capital LP acquired a new stake in shares of Harmony Biosciences in the 4th quarter worth about $49,894,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Harmony Biosciences by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company's stock worth $41,739,000 after acquiring an additional 160,490 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Up 2.4%

Harmony Biosciences stock opened at $35.91 on Tuesday. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.47 and a beta of 0.82. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company's 50-day moving average price is $31.50 and its two-hundred day moving average price is $33.99. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same quarter last year, the firm posted $0.67 EPS. The business's revenue for the quarter was up 19.5% on a year-over-year basis. On average, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Cantor Fitzgerald raised shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Mizuho increased their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Finally, UBS Group lowered their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $52.78.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.